Literature DB >> 28797806

Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges.

Soheil Tavakolpour1.   

Abstract

There is generally no cure for autoimmune disorders, but the symptoms can be managed. Currently available drugs/treatments are more potent than those in the past decades. However, finding the right drug and right patients has remained a serious problem. We should revise our diagnosis criteria to more accurate ones. During the recent years, personalized medicine has attracted much attention. However, it needs to be well-explained for autoimmune diseases. Personalized medicine aims to find the most optimum drugs for a patient. Hence, recognizing the drugs based on genetics and molecular profile of patients, needs a comprehensive protocol. This study attempted to discuss the most practical and effective ways for identifying right patient and right drug. Patients should be divided into subpopulations. According to the last diagnosis criteria and therapeutic options, it was attempted to highlight the gaps or contradictions in current understanding and suggest what the future of research in this area may hold. Various factors could be considered, including genes variants, genes expression, epigenetic alterations, immune responses, and also basic and obvious characteristics (sex, age, ethnic, etc.). Moreover, advantages, disadvantages, obstacles, and opportunities during the personalized medicine for autoimmune diseases have been discussed in great detail. Finally, creation of a global library that covers all the aspects of personalized medicines for different types of autoimmune disease was suggested. In conclusion, revising diagnosis and treatments of autoimmune diseases toward personalized medicine could be the revolutionary step for having more effective and safer therapeutic options.
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Immunology diagnosis; Personalized medicine; Pharmacogenomics

Mesh:

Substances:

Year:  2017        PMID: 28797806     DOI: 10.1016/j.imlet.2017.08.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

Review 2.  The effect of immunomodulatory properties of naringenin on the inhibition of inflammation and oxidative stress in autoimmune disease models: a systematic review and meta-analysis of preclinical evidence.

Authors:  Mina Alimohammadi; Rebar N Mohammad; Ali Rahimi; Fatemeh Faramarzi; Reza Alizadeh-Navaei; Alireza Rafiei
Journal:  Inflamm Res       Date:  2022-07-08       Impact factor: 4.575

3.  Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies.

Authors:  Madi El-Haj; Dimitri Kanovitch; Yaron Ilan
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

4.  Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls.

Authors:  Pegah Shahbazian; Maryam Izad; Maryam Daneshpazhooh; Hossein Mortazavi; Zahra Salehi; Shirin Behruzifar; Soheil Tavakolpour; Arghavan Azizpour
Journal:  Dermatol Pract Concept       Date:  2021-04-12

5.  Cloning, expression and identification of KTX-Sp4, a selective Kv1.3 peptidic blocker from Scorpiops pococki.

Authors:  Yan Zou; Feng Zhang; Yaxian Li; Yuanfang Wang; Yi Li; Zhengtao Long; Shujuan Shi; Li Shuai; Jiukai Liu; Zhiyong Di; Shijin Yin
Journal:  Cell Biosci       Date:  2017-11-06       Impact factor: 7.133

6.  Rapid microbial identification and antimicrobial susceptibility testing to drive better patient care: an evolving scenario.

Authors:  Volkan Özenci; Gian Maria Rossolini
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

7.  Using Gene Expression Analysis to Understand Complex Autoimmune Skin Disease Patients: A Series of Four Canine Cutaneous Lupus Erythematosus Cases.

Authors:  Alice A Amudzi; Cesar Piedra-Mora; Diana Junyue Ma; Neil B Wong; Clement N David; Nicholas A Robinson; Ramón M Almela; Jillian M Richmond
Journal:  Front Vet Sci       Date:  2022-02-24

Review 8.  Scutellaria baicalensis georgi is a promising candidate for the treatment of autoimmune diseases.

Authors:  Jun Wang; Shanshan Chen; Jizhou Zhang; Jiasi Wu
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

9.  Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.

Authors:  Lam C Tsoi; Matthew T Patrick; Shao Shuai; Mrinal K Sarkar; Sunyi Chi; Bethany Ruffino; Allison C Billi; Xianying Xing; Ranjitha Uppala; Cheng Zang; Joseph Fullmer; Zhi He; Emanual Maverakis; Nehal N Mehta; Bethany E Perez White; Spiro Getsios; Yolanda Helfrich; John J Voorhees; J Michelle Kahlenberg; Stephan Weidinger; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2021-07-31       Impact factor: 14.290

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.